» Articles » PMID: 32336983

Febrile Neutropenia in Paediatric Oncology

Overview
Specialty Pediatrics
Date 2020 Apr 28
PMID 32336983
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Febrile neutropenia (FN) is a common and dangerous consequence of myelosuppressive chemotherapy but can occur as part of the disease processes. Bacterial bloodstream infection is the most commonly diagnosed cause of febrile neutropenia, with Gram-positive organisms most frequently isolated. However, Gram-negative organisms are becoming more prevalent, with a worrying trend towards resistant organisms. When FN is prolonged, lasting for more than 5 days, there is an increased risk of invasive fungal infections. Prompt recognition, diagnosis and initiation of treatment with broad-spectrum antibiotics are essential to avoid complications and prevent rapid progression to sepsis and possible death. This short article summarises the definition, causes, pathogenesis, applied physiology and management of FN in children.

Citing Articles

Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children.

Hoshino W, da Silva A, Pignatari A, Gales A, Carlesse F Braz J Infect Dis. 2025; 29(2):104515.

PMID: 39985933 PMC: 11893299. DOI: 10.1016/j.bjid.2025.104515.


Human pegivirus -1 (HPgV-1) RNA frequency and genotype distribution in pediatric oncology patients with febrile neutropenia.

da Silva A, de Campos G, Altizani G, Barros A, Junqueira D, Kashima S Virus Res. 2024; 350():199479.

PMID: 39374843 PMC: 11736395. DOI: 10.1016/j.virusres.2024.199479.


Diagnostic and Therapeutic Challenge Caused by and spp. Infections in a Pediatric Patient as a Complication of Acute Lymphoblastic Leukemia Treatment: A Case Report and Literature Review.

Zaj N, Kopyt W, Kamizela E, Zarychta J, Kowalczyk A, Lejman M Pathogens. 2024; 13(9).

PMID: 39338963 PMC: 11435145. DOI: 10.3390/pathogens13090772.


Anaesthesia for children with cancer.

Kostense Z, de Ruiter J BJA Educ. 2024; 24(7):231-237.

PMID: 38899313 PMC: 11184477. DOI: 10.1016/j.bjae.2024.03.007.


Infection-related mortality and infection control practices in childhood acute myeloid leukemia in a limited resource setting: Experience with the Indonesian national protocol.

Supriyadi E, Purwanto I, Widiastuti Z, Armytasari I, Sandi S, Ardianto B Belitung Nurs J. 2024; 10(2):185-191.

PMID: 38690309 PMC: 11056831. DOI: 10.33546/bnj.3139.


References
1.
Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M . Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016; 27(suppl 5):v111-v118. DOI: 10.1093/annonc/mdw325. View

2.
Haeusler G, Thursky K, Mechinaud F, Babl F, De Abreu Lourenco R, Slavin M . Predicting Infectious ComplicatioNs in Children with Cancer: an external validation study. Br J Cancer. 2017; 117(2):171-178. PMC: 5520507. DOI: 10.1038/bjc.2017.154. View

3.
Alexander S, Wade K, Hibberd P, Parsons S . Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002; 24(1):38-42. DOI: 10.1097/00043426-200201000-00011. View

4.
Paolino J, Mariani J, Lucas A, Rupon J, Weinstein H, Abrams A . Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia. Pediatr Blood Cancer. 2019; 66(7):e27679. DOI: 10.1002/pbc.27679. View

5.
Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann R, Beauchemin M . Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. J Clin Oncol. 2017; 35(18):2082-2094. DOI: 10.1200/JCO.2016.71.7017. View